English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Growing knowledge on T-cell lymphoma (TCL) biology has led to the understanding that TCLs harbor derangements in proteins modulating epigenetic control. Some such derangements include mutations in TET2, IDH2, DNMT3A, EP300, and CBP. In addition, overexpression of epigenetic modifiers such as EZH2 also exists in the absence of mutations. HDAC inhibitors are approved for use in relapsed T-cell lymphoma. There may be unique methods to targeting epigenetic derangements using new agents such as DNMT, EZH2, IDH, and BET inhibitors to name a few. In this chapter, we will review and explore unique methods for therapeutic targeting of epigenetic machinery for TCL.

Unique Therapeutic Approaches for Targeting Epigenetic Machinery in T-cell Lymphoma